University of Pennsylvania

Northwest Biotherapeutics has commenced construction of its first Grade C manufacturing suite at the Sawston, UK facility, which will more than double the company's current DCVax production capacity.

University of Pennsylvania researchers demonstrated that CAR T cell therapy using regulatory T cells (Tregs) targeting oxidized LDL reduced atherosclerotic plaque burden by approximately 70% in mice after twelve weeks of treatment.

University of Pennsylvania researchers discovered that hydralazine, a 70-year-old blood pressure medication, can prevent glioblastoma brain cancer cells from growing by targeting a critical oxygen-sensing enzyme called ADO.

The first patients at the University of Pennsylvania who received experimental CAR T cell therapy for leukemia showed remarkable results, with the first patient's biopsy showing no evidence of leukemia.

Doctors plan to request FDA approval this winter for a clinical trial testing CRISPR base editing in seven different urea cycle disorders, following the successful treatment of baby KJ with CPS1 deficiency.

Vasa Therapeutics received FDA IND clearance for VS-041, a novel small molecule inhibitor of matrix metalloproteinases, to begin Phase 1c trials in HFpEF patients.

A phase 2a trial of CAN-2409 viral immunotherapy showed median overall survival of 24.5 months in 46 patients with advanced NSCLC who failed immune checkpoint inhibitor therapy.

Researchers at the University of Gothenburg found that semaglutide, a diabetes and weight loss medication, reduced cocaine self-administration by 26% in rats compared to control animals.

A first-of-its-kind clinical trial demonstrated that repurposed cancer drugs can effectively target dormant breast cancer cells, clearing them in 80% of participants and potentially preventing cancer recurrence.

Northwest Biotherapeutics has completed its acquisition of Advent BioServices Ltd., making it a wholly owned subsidiary to enable fully integrated operations and manufacturing scale-up.